Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2

Loading...
Thumbnail Image
File version
Version of Record (VoR)
Author(s)
Scott, Tristan A
Supramaniam, Aroon
Idris, Adi
Cardoso, Angelo A
Shrivastava, Surya
Kelly, Gabrielle
Grepo, Nicole A
Soemardy, Citradewi
Ray, Roslyn M
McMillan, Nigel AJ
Morris, Kevin
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2022
Size
File type(s)
Location
License
http://creativecommons.org/licenses/by-nc-nd/4.0/
Abstract

SARS-CoV-2 (CoV-2) viral infection results in COVID-19 disease, which has caused significant morbidity and mortality worldwide. A vaccine is crucial to curtail the spread of SARS-CoV-2, while therapeutics will be required to treat ongoing and reemerging infections of SARS-CoV-2 and COVID-19 disease. There are currently no commercially available effective anti-viral therapies for COVID-19, urging the development of novel modalities. Here, we describe a molecular therapy specifically targeted to neutralize SARS-CoV-2, which consists of extracellular vesicles (EVs) containing a novel fusion tetraspanin protein, CD63, embedded within an anti-CoV-2 nanobody. These anti-CoV-2-enriched EVs bind SARS-CoV-2 spike protein at the receptor-binding domain (RBD) site and can functionally neutralize SARS-CoV-2. This work demonstrates an innovative EV-targeting platform that can be employed to target and inhibit the early stages of SARS-CoV-2 infection.

Journal Title
Molecular Therapy – Methods & Clinical Development
Conference Title
Book Title
Edition
Volume
24
Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© 2022 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Item Access Status
Note
Access the data
Related item(s)
Subject
Medical biotechnology
Science & Technology
Life Sciences & Biomedicine
Medicine, Research & Experimental
Research & Experimental Medicine
STEM-CELLS
Persistent link to this record
Citation
Scott, TA; Supramaniam, A; Idris, A; Cardoso, AA; Shrivastava, S; Kelly, G; Grepo, NA; Soemardy, C; Ray, RM; McMillan, NAJ; Morris, K, Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2, Molecular Therapy – Methods & Clinical Development, 2022, 24, pp. 355-366
Collections